[1]
Rhebergen D, Graham R. The re-labelling of dysthymic disorder to persistent depressive disorder in DSM-5: old wine in new bottles? Current opinion in psychiatry. 2014 Jan:27(1):27-31. doi: 10.1097/YCO.0000000000000022. Epub
[PubMed PMID: 24270481]
Level 3 (low-level) evidence
[2]
Freeman HL. Historical and nosological aspects of dysthymia. Acta psychiatrica Scandinavica. Supplementum. 1994:383():7-11
[PubMed PMID: 7942068]
[3]
Brieger P, Marneros A. Dysthymia and cyclothymia: historical origins and contemporary development. Journal of affective disorders. 1997 Sep:45(3):117-26
[PubMed PMID: 9298424]
[4]
Brieger P,Marneros A, [The dysthymia concept: current and historical aspects--an overview]. Fortschritte der Neurologie-Psychiatrie. 1995 Oct;
[PubMed PMID: 8529990]
Level 3 (low-level) evidence
[5]
Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. The American journal of psychiatry. 2000 Oct:157(10):1552-62
[PubMed PMID: 11007705]
Level 1 (high-level) evidence
[6]
Kendler KS, Gardner CO, Prescott CA. Toward a comprehensive developmental model for major depression in men. The American journal of psychiatry. 2006 Jan:163(1):115-24
[PubMed PMID: 16390898]
[7]
Kessler RC, Ormel J, Petukhova M, McLaughlin KA, Green JG, Russo LJ, Stein DJ, Zaslavsky AM, Aguilar-Gaxiola S, Alonso J, Andrade L, Benjet C, de Girolamo G, de Graaf R, Demyttenaere K, Fayyad J, Haro JM, Hu Cy, Karam A, Lee S, Lepine JP, Matchsinger H, Mihaescu-Pintia C, Posada-Villa J, Sagar R, Ustün TB. Development of lifetime comorbidity in the World Health Organization world mental health surveys. Archives of general psychiatry. 2011 Jan:68(1):90-100. doi: 10.1001/archgenpsychiatry.2010.180. Epub
[PubMed PMID: 21199968]
Level 3 (low-level) evidence
[8]
Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of general psychiatry. 2005 Jun:62(6):593-602
[PubMed PMID: 15939837]
Level 3 (low-level) evidence
[9]
Vandeleur CL, Fassassi S, Castelao E, Glaus J, Strippoli MF, Lasserre AM, Rudaz D, Gebreab S, Pistis G, Aubry JM, Angst J, Preisig M. Prevalence and correlates of DSM-5 major depressive and related disorders in the community. Psychiatry research. 2017 Apr:250():50-58. doi: 10.1016/j.psychres.2017.01.060. Epub 2017 Jan 23
[PubMed PMID: 28142066]
[10]
Seedat S, Scott KM, Angermeyer MC, Berglund P, Bromet EJ, Brugha TS, Demyttenaere K, de Girolamo G, Haro JM, Jin R, Karam EG, Kovess-Masfety V, Levinson D, Medina Mora ME, Ono Y, Ormel J, Pennell BE, Posada-Villa J, Sampson NA, Williams D, Kessler RC. Cross-national associations between gender and mental disorders in the World Health Organization World Mental Health Surveys. Archives of general psychiatry. 2009 Jul:66(7):785-95. doi: 10.1001/archgenpsychiatry.2009.36. Epub
[PubMed PMID: 19581570]
Level 3 (low-level) evidence
[11]
Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Archives of general psychiatry. 2005 Oct:62(10):1097-106
[PubMed PMID: 16203955]
Level 3 (low-level) evidence
[12]
Kessler RC, Birnbaum H, Bromet E, Hwang I, Sampson N, Shahly V. Age differences in major depression: results from the National Comorbidity Survey Replication (NCS-R). Psychological medicine. 2010 Feb:40(2):225-37. doi: 10.1017/S0033291709990213. Epub 2009 Jun 17
[PubMed PMID: 19531277]
Level 3 (low-level) evidence
[13]
Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Archives of general psychiatry. 1997 Jul:54(7):597-606
[PubMed PMID: 9236543]
[15]
Nutt DJ, Baldwin DS, Clayton AH, Elgie R, Lecrubier Y, Montejo AL, Papakostas GI, Souery D, Trivedi MH, Tylee A. Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. The Journal of clinical psychiatry. 2006:67 Suppl 6():46-9
[PubMed PMID: 16848678]
Level 3 (low-level) evidence
[16]
Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA, Berman RM, Charney DS, Krystal JH. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Archives of general psychiatry. 1999 Nov:56(11):1043-7
[PubMed PMID: 10565505]
[17]
Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ, Hulshoff Pol HE, Kahn RS. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Human brain mapping. 2009 Nov:30(11):3719-35. doi: 10.1002/hbm.20801. Epub
[PubMed PMID: 19441021]
Level 1 (high-level) evidence
[18]
Uher R, Payne JL, Pavlova B, Perlis RH. Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV. Depression and anxiety. 2014 Jun:31(6):459-71. doi: 10.1002/da.22217. Epub 2013 Nov 22
[PubMed PMID: 24272961]
[19]
Korn CS, Currier GW, Henderson SO. "Medical clearance" of psychiatric patients without medical complaints in the Emergency Department. The Journal of emergency medicine. 2000 Feb:18(2):173-6
[PubMed PMID: 10699517]
[20]
Conigliaro A, Benabbas R, Schnitzer E, Janairo MP, Sinert R. Protocolized Laboratory Screening for the Medical Clearance of Psychiatric Patients in the Emergency Department: A Systematic Review. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2018 May:25(5):566-576. doi: 10.1111/acem.13368. Epub 2018 Mar 9
[PubMed PMID: 29266617]
Level 1 (high-level) evidence
[21]
Ordas DM, Labbate LA. Routine screening of thyroid function in patients hospitalized for major depression or dysthymia? Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. 1995 Dec:7(4):161-5
[PubMed PMID: 8721889]
[22]
Kroenke K, Spitzer RL, Williams JB, Löwe B. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. General hospital psychiatry. 2010 Jul-Aug:32(4):345-59. doi: 10.1016/j.genhosppsych.2010.03.006. Epub 2010 May 7
[PubMed PMID: 20633738]
Level 1 (high-level) evidence
[23]
Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. The Journal of clinical psychiatry. 2009 Sep:70(9):1219-29. doi: 10.4088/JCP.09r05021. Epub
[PubMed PMID: 19818243]
Level 1 (high-level) evidence
[24]
Cuijpers P, van Straten A, Warmerdam L, Andersson G. Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: a meta-analysis. Depression and anxiety. 2009:26(3):279-88. doi: 10.1002/da.20519. Epub
[PubMed PMID: 19031487]
Level 1 (high-level) evidence
[25]
Linde K, Kriston L, Rücker G, Jamil S, Schumann I, Meissner K, Sigterman K, Schneider A. Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. Annals of family medicine. 2015 Jan-Feb:13(1):69-79. doi: 10.1370/afm.1687. Epub
[PubMed PMID: 25583895]
Level 1 (high-level) evidence
[26]
Meister R, von Wolff A, Mohr H, Härter M, Nestoriuc Y, Hölzel L, Kriston L. Comparative Safety of Pharmacologic Treatments for Persistent Depressive Disorder: A Systematic Review and Network Meta-Analysis. PloS one. 2016:11(5):e0153380. doi: 10.1371/journal.pone.0153380. Epub 2016 May 17
[PubMed PMID: 27187783]
Level 2 (mid-level) evidence
[27]
Meister R, Jansen A, Härter M, Nestoriuc Y, Kriston L. Placebo and nocebo reactions in randomized trials of pharmacological treatments for persistent depressive disorder. A meta-regression analysis. Journal of affective disorders. 2017 Jun:215():288-298. doi: 10.1016/j.jad.2017.03.024. Epub 2017 Mar 9
[PubMed PMID: 28363152]
Level 1 (high-level) evidence
[28]
Cuijpers P, Karyotaki E, Weitz E, Andersson G, Hollon SD, van Straten A. The effects of psychotherapies for major depression in adults on remission, recovery and improvement: a meta-analysis. Journal of affective disorders. 2014 Apr:159():118-26. doi: 10.1016/j.jad.2014.02.026. Epub 2014 Feb 24
[PubMed PMID: 24679399]
Level 1 (high-level) evidence
[29]
Cuijpers P, van Straten A, Andersson G, van Oppen P. Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. Journal of consulting and clinical psychology. 2008 Dec:76(6):909-22. doi: 10.1037/a0013075. Epub
[PubMed PMID: 19045960]
Level 2 (mid-level) evidence
[30]
Furukawa TA, Efthimiou O, Weitz ES, Cipriani A, Keller MB, Kocsis JH, Klein DN, Michalak J, Salanti G, Cuijpers P, Schramm E. Cognitive-Behavioral Analysis System of Psychotherapy, Drug, or Their Combination for Persistent Depressive Disorder: Personalizing the Treatment Choice Using Individual Participant Data Network Metaregression. Psychotherapy and psychosomatics. 2018:87(3):140-153. doi: 10.1159/000489227. Epub 2018 May 30
[PubMed PMID: 29847831]
[31]
Hung CI, Liu CY, Yang CH. Persistent depressive disorder has long-term negative impacts on depression, anxiety, and somatic symptoms at 10-year follow-up among patients with major depressive disorder. Journal of affective disorders. 2019 Jan 15:243():255-261. doi: 10.1016/j.jad.2018.09.068. Epub 2018 Sep 18
[PubMed PMID: 30248637]
[32]
Katon W, Ciechanowski P. Impact of major depression on chronic medical illness. Journal of psychosomatic research. 2002 Oct:53(4):859-63
[PubMed PMID: 12377294]
[33]
Zeiss AM, Karlin BE. Integrating mental health and primary care services in the Department of Veterans Affairs health care system. Journal of clinical psychology in medical settings. 2008 Mar:15(1):73-8. doi: 10.1007/s10880-008-9100-4. Epub 2008 Feb 21
[PubMed PMID: 19104957]